Maintenance treatment for myasthenia gravis after efgartigimod
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of myasthenia gravis.
- You are already eligible to take efgartigimod, based on standard medical guidelines and a blood test.
- Your MG symptoms significantly affect daily life—either a score of 11 or more on the MG-ADL scale, or a score of 6 to 10 with most trouble coming from things other than eye symptoms.
- You have not had a previous B-cell depleting treatment (like rituximab) or certain other strong immune therapies.
- You do not have another active autoimmune disease (like lupus or rheumatoid arthritis) or an immune deficiency.
- You have not had a bad reaction to efgartigimod or similar drugs in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
This study tests whether continuing efgartigimod after a myasthenia gravis crisis helps keep symptoms under control and prevent future flare-ups. It is for people who have already responded to one round of this treatment.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests the drug efgartigimod given before and after surgery for people with myasthenia gravis and a thymoma. The goal is to see if it helps improve symptoms and recovery around the operation.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.